Meryl Kelada

RA II, chemical biology at Empress Therapeutics

Meryl Kelada has a diverse range of work experience. Meryl started their career as an Intern at the Egyptian Atomic Energy Authority in 2018. Meryl then joined the Massachusetts College of Pharmacy and Health Sciences as a Pharmacy Student, where they achieved a Cumulative GPA of 3.9/4.0. During their time at the college, they also worked as a Graduate Teaching Assistant, providing guidance and support to students during lab work and assisting in the maintenance of laboratories. Additionally, they worked as a Proctor, overseeing exams and ensuring a distraction-free environment for students.

After completing their studies, Meryl joined Kojin Therapeutics in 2021 as a Research Associate I in Discovery Biology. In this role, they optimized and utilized cell-based assays to support medicinal chemistry efforts and build structure-activity relationships. Meryl gained experience with various mammalian cell lines and utilized assays such as BCA, CTG, and GSH-glo assays.

Currently, Meryl is employed at Empress Therapeutics as an RA II in chemical biology, starting in 2022. No end date is provided for this role.

Meryl Kelada earned a Bachelor's degree in Pharmacy from Ain Shams University, where they studied from 2012 to 2017. Meryl then pursued a Master's degree in Medicinal Chemistry at the Massachusetts College of Pharmacy and Health Sciences from 2018 to 2020. In addition to their formal education, Kelada obtained a Certificate of Appreciation For Presenting a Poster from the United Scientific Group in November 2019 and completed a course on Medicinal Chemistry: The Molecular Basis of Drug Discovery from edX in January 2018.

Links

Previous companies

Kojin Therapeutics logo

Timeline

  • RA II, chemical biology

    February, 2022 - present